ERBB2 and breast carcinoma: A large meta-analysis of pivotal clinical trials has demonstrated improvements in both DFS and OS with 12-month adjuvant trastuzumab treatment of HER2-positive early breast cancer compared with no use of anti-HER2 treatment13.